Photobiomodulation in the treatment of patients with non-center-involving diabetic macular oedema
Tang J, Herda AA, Kern TS
The British journal of ophthalmology · 57 citations
How it was studied
- Design
- Case-control study (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- National Eye Institute
- Government
- NEI NIH HHS
- Grants
- National Eye Institute (R01EY022938); National Eye Institute (R01 EY000300); National Eye Institute (R01EY00300)
Based on 2 listed funder(s).
Publication
- Published
- 2014-03-28 · Br J Ophthalmol · vol. 98 · issue 8 · pp. 1013–1015
- Publisher
- BMJ
- Cited
- 77 citations · more than 95% of similar papers · 4.6× the field average
- Impact
- Top 10% most cited in its field
- References
- 8 works
- Access
- Open access (repository copy)
- Research areas
- Laser Applications in Dentistry and Medicine · Retinal Diseases and Treatments · Dermatologic Treatments and Research
- Keywords
- Medicine, Diabetic retinopathy, Diabetes mellitus, Visual acuity, Adverse effect, Ophthalmology, Retinal, Retinopathy, Surgery, Internal medicine
- MeSH
- humans, diabetic retinopathy, phototherapy, case-control studies, adult, aged, middle aged, point-of-care systems, male, macular edema
3 authors
From US
- Johnny Cheuk On Tang · correspondingLouis Stokes Cleveland VA Medical Center
- Ashley A. HerdaUniversity of Kansas Medical Center
- Timothy S. KernLouis Stokes Cleveland VA Medical Center; University School; Case Western Reserve University
Abstract
Purpose
Far-red/near-infrared phototherapy or photobiomodulation (PBM) has recently been reported to be an effective and non-invasive treatment method to inhibit lesions of diabetic retinopathy (DR) in animals. This study investigated the safety and efficacy of PBM in diabetic patients to treat non-center-involving diabetic macular oedema (NCDME).
Methods
This was a non-randomised, consecutive, case series, where 4 patients with type 2 diabetes with NCDME were treated for 160 s per day with PBM for 2-9 months. Demographic data including age, sex, HbA1c%, electronic ETDRS visual acuity, and retinal and macular thickness were measured using spectral domain ocular coherence tomography (SD-OCT) before and after treatment.
Results
Four eyes of 4 patients were treated, with fellow eyes serving as untreated controls. Daily PBM treatment for only 80 s per treatment twice daily caused a significant reduction in focal retinal thickening in all 4 treated eyes. No adverse effects attributable to therapy were noted by the patients or study investigators during the study period.
Conclusions
PBM potentially offers a non-invasive and cost-effective therapeutic option for patients with NCDME. Further studies of this therapeutic option in DR are warranted.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.